Theravance Biopharma Cuts Workforce by 50% Following Failed Drug Trial

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions Rhea-AI Impact (High) Rhea-AI Sentiment (Neutral) Tags clinical trial Rhea-AI Summary English Arabic French German Italian Korean Spanish Theravance Biopharma (NASDAQ: TBPH) reported that the Phase 3 CYPRESS study of ampreloxetine did not meet the primary OHSA composite endpoint, and the company will wind down the program. The Board's Strategic Review Committee is accelerating a review of alternatives, including a potential sale. The company is restructuring to cut operating expenses ~60% (≈$70M run-rate), expect ~50% workforce reduction, and forecasts $60–$70M annualized cash flow starting Q3 2026. Cash was $326.5M at 12/31/2025; approximately $400M expected EoQ1 2026, and a $100M TRELEGY milestone is expected in 2026. Loading... Loading translation... Positive Expected cash balance of approximately $400 million at end of Q1 2026 YUPELRI FY2025 U.S. net sales of $266.6 million (+12% YoY) Restructuring targets $70 million annual run-rate cost savings Projected annualized cash flow of $60–$70 million starting Q3 2026 Negative Phase 3 CYPRESS failed to meet primary endpoint for ampreloxetine Decision to wind down ampreloxetine program eliminates future upside from that asset Workforce reduction impacts ~50% of employees and incurs $5–$7 million severance costs R&D organization will be fully wound down, reducing discovery/redevelopment optionality News Market Reaction – TBPH -26.33% 4 alerts -26.33% News Effect -10.3% Trough Tracked -$343M Valuation Impact $960M Market Cap 0.0x Rel. Volume On the day this news was published, TBPH declined 26.33% , reflecting a significant negative market reaction. Argus tracked a trough of -10.3% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $343M from the company's valuation, bringing the market cap to $960M at that time. Data tracked by StockTitan Argus on the day of publication. Key Figures Cash balance: $326.5M YUPELRI FY25 sales: $266.6M YUPELRI Q4 sales: $70.6M +5 more 8 metrics Cash balance $326.5M Cash as of Dec 31, 2025; no debt YUPELRI FY25 sales $266.6M FY 2025 U.S. net sales recognized by Viatris (+12% YoY) YUPELRI Q4 sales $70.6M Q4 2025 U.S. net sales, +6% YoY YUPELRI milestone $25M Sales-based milestone from Viatris; cash received Jan 2026 TRELEGY milestone $50M Milestone from Royalty Pharma after FY 2025 TRELEGY sales; received Feb 2026 TRELEGY FY25 sales $3.91B GSK reported FY 2025 global TRELEGY net sales 2025 operating expenses $110M 2025 preliminary actual operating expenses before 60% reduction plan Severance costs $5–$7M Expected one-time cash severance costs from restructuring {"@context":"https://schema.org","@type":"Table","about":"Key financial figures from this news article","cssSelector":".context-figures-grid","name":"Key Figures","description":"Important metrics and data points extracted from the article","mainEntity":{"@type":"ItemList","numberOfItems":8,"itemListElement":[{"@type":"ListItem","position":1,"name":"Cash balance","description":"$326.5M (Cash as of Dec 31, 2025; no debt)"},{"@type":"ListItem","position":2,"name":"YUPELRI FY25 sales","description":"$266.6M (FY 2025 U.S. net sales recognized by Viatris (+12% YoY))"},{"@type":"ListItem","position":3,"name":"YUPELRI Q4 sales","description":"$70.6M (Q4 2025 U.S. net sales, +6% YoY)"},{"@type":"ListItem","position":4,"name":"YUPELRI milestone","description":"$25M (Sales-based milestone from Viatris; cash received Jan 2026)"},{"@type":"ListItem","position":5,"name":"TRELEGY milestone","description":"$50M (Milestone from Royalty Pharma after FY 2025 TRELEGY sales; received Feb 2026)"},{"@type":"ListItem","position":6,"name":"TRELEGY FY25 sales","description":"$3.91B (GSK reported FY 2025 global TRELEGY net sales)"},{"@type":"ListItem","position":7,"name":"2025 operating expenses","description":"$110M (2025 preliminary actual operating expenses before 60% reduction plan)"},{"@type":"ListItem","position":8,"name":"Severance costs","description":"$5–$7M (Expected one-time cash severance costs from restructuring)"}]}} Market Reality Check Price: $13.96 Vol: Volume 756,365 is above t... normal vol $13.96 Last Close Volume Volume 756,365 is above the 20-day average of 518,576 (relative volume 1.46 ) ahead of this update. normal Technical Shares at $18.95 are trading above the $14.88 200-day MA and remain 9.89% below the 52-week high of $21.03 . Peers on Argus Pre-news, TBPH was up 3.84% with mixed moves among biotech peers; only one peer ... 1 Up Pre-news, TBPH was up 3.84% with mixed moves among biotech peers; only one peer (GYRE) appeared on the momentum scanner, up 2.40% , suggesting stock-specific dynamics rather than a broad sector move. Previous Clinical trial Reports 3 past events · Latest: